Mesa Laboratories Inc

While the long and medium-term trends remain bullish in Stage 2, recent price action has pulled back below the short EMAs and into the 50 SMA support area. Short-term timing is neutral, and execution should be deferred until price reclaims and accepts above the 9/21 EMAs. We will stalk pullbacks into the rising EMAs or the 50 SMA for a favorable entry.

• ↑Revenue up 1% to $60.1M; operating income jumped 129% to $7.03M.
• ↑Operating cash flow rose to $14.7M, up $12.8M YoY on stronger collections.
• ↓SDC segment organic revenue declined 3.6% amid delivery reliability issues.